Key facts
- Notable investors include Beijing Shangshi Investment Management, Me Too Investment, Renai Group.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for GD BioPharma
- ·The full record, as it builds
Funding rounds
No funding rounds for GD BioPharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GD BioPharma
Developer of innovative drugs intended for pharmaceutical developers and research organizations. The company focuses on the research and development of Targeted drug design, and offers drug chemical synthesis and pharmacological testing platform, which includes a computer-aided drug design platform, medicinal chemical synthesis platform, pharmacology and drug targeting mechanism research platform, thereby enabling clients to advance drug development solutions.
- Sector
- Healthcare
- HQ
- Tianjin, China
- Founded
- 2010
- Employees
- 30
- Website
- guduibio.com/
- Ownership
- Privately Held (backing)
GD BioPharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GD BioPharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GD BioPharma in its N-PORT filings yet. We sweep new filings monthly.